Background
Raludotatug is a humanized immunoglobulin G1-kappa, anti-CDH6 monoclonal antibody. Raludotatug is an antineoplastic.• Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models., PMID:38205802• Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers., PMID:28526733• Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface., PMID:27563818• Characterization of the role for cadherin 6 in the regulation of human endometrial receptivity., PMID:32600462• Alterations in expression of cadherin-6 and E-cadherin during kidney development and in renal cell carcinoma., PMID:10940709• Mesothelin promotes the migration of endometrioid carcinoma and is associated with the MELF pattern., PMID:39182448• The GLI2/CDH6 axis enhances migration, invasion and mitochondrial fission of stomach adenocarcinoma cells., PMID:37523816• Cadherin 6 promotes neural crest cell detachment via F-actin regulation and influences active Rho distribution during epithelial-to-mesenchymal transition., PMID:24917505• Kidney development in cadherin-6 mutants: delayed mesenchyme-to-epithelial conversion and loss of nephrons., PMID:10864459• Cadherin 6 is a new RUNX2 target in TGF-β signalling pathway., PMID:24069422